Logo Image
Opinion|Videos|October 11, 2024

Additional Immunotherapies on the Horizon for LS-SCLC

Key Takeaways

  • Atezolizumab is being tested in the NRG-LU005 trial for limited-stage SCLC, assessing its efficacy alongside chemoradiation.
  • The NRG-LU005 trial is a randomized, phase III study comparing chemoradiation with or without atezolizumab.
SHOW MORE

Panelists discuss how atezolizumab is being investigated in the NRG-LU005 trial for limited-stage small cell lung cancer (SCLC), comparing its trial design with that of the ADRIATIC study, while also exploring the potential benefits of using a single immunotherapy across all SCLC stages and considering treatment strategies for patients who progress from limited-stage to extensive-stage disease while on immunotherapy.

Episodes in this series

Atezolizumab is also being investigated in the NRG-LU005 trial in patients with limited-stage small cell lung cancer (SCLC).

  • What potential role could atezolizumab have in patients with limited-stage disease?
  • What is the design of this trial?
  • How does the trial design differ from the ADRIATIC trial?

Are there synergies or efficiencies in using a single immunotherapy in all stages of SCLC?

If a patient progresses from limited-stage to extensive-stage disease on immunotherapy, do you switch therapies or continue the same regimen?